U.S. markets close in 4 hours 31 minutes

Viracta Therapeutics, Inc. (VIRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.4800-0.0150 (-3.03%)
As of 11:28AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.4950
Bid0.4730 x 3200
Ask0.4999 x 800
Day's Range0.4768 - 0.5247
52 Week Range0.4700 - 2.4700
Avg. Volume104,396
Market Cap18.54M
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-1.2400
Earnings DateNov 09, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VIRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Viracta Therapeutics, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 18,000 employees.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

    Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma showing an overall response rate and complete response rate of 40% Reported interim data from the Phase 1b/2 trial of Nana-val in advanced EBV+ solid tumors with confirmed partial responses at higher doses and no dose-limiting toxicities observed to date SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX)

  • GlobeNewswire

    Viracta Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Company’s Management will participate in upcoming investor conferences in November. Details on the conferences can be found below: Stifel 2023 Healthcare Conference Presentation Date: Wednesday, November 15, 2023 Presentation Time: 10:20 – 10:50 A

  • GlobeNewswire

    Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

    Preliminary clinical data from patients with relapsed/refractory EBV+ peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from the Phase 1b/2 study demonstrated median duration of response extended to 17.3 months Additional response and durability data in patients with relapsed/refractory EBV+ diffuse large B-cell lymphoma in the Phase 1b/2 study demonstrated sustained overall response rate of 67%; median duration of response